Morning Briefing
Summaries of health policy coverage from major news organizations
Gilead Submits Application To FDA Asking For PrEP Approval For Truvada
Pharmaceutical company Gilead Sciences on Thursday submitted an application to the FDA asking the agency to approve its antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among adults, a Gilead press release reports. "If the [application] is approved, Truvada would be the first agent indicated for uninfected individuals to reduce the risk of acquiring HIV through sex," the press release notes (12/15).
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
